 |
PDBsum entry 1ab9
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Complex (serine protease/peptide)
|
PDB id
|
|
|
|
1ab9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
X-Ray crystal structure of a dipeptide-Chymotrypsin complex in an inhibitory interaction.
|
 |
|
Authors
|
 |
A.Kashima,
Y.Inoue,
S.Sugio,
I.Maeda,
T.Nose,
Y.Shimohigashi.
|
 |
|
Ref.
|
 |
Eur J Biochem, 1998,
255,
12-23.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The dipeptide D-leucyl-L-phenylalanyl p-fluorobenzylamide (D-Leu-Phe-NH-BzlF)
inhibits chymotrypsin strongly in a competitive manner with the Ki value of 0.61
microM [Shimohigashi, Y., Maeda, I., Nose, T., Ikesue, K., Sakamoto, H., Ogawa,
T., Ide, Y., Kawahara, M., Nezu, T., Terada, Y., Kawano, K. & Ohno, M.
(1996) J. Chem. Soc. Perkin Trans. 1, 2479-2485]. The structure/activity studies
have suggested a unique inhibitory conformation, in which the C-terminal benzyl
group fits the chymotrypsin S1 site and the hydrophobic core constructed by the
side chains of D-Leu-Phe fits the S2 or S1' site. To verify this assumption, the
molecular structure of the complex between the dipeptide and gamma-chymotrypsin
has been determined crystallographically. Gamma-chymotrypsin itself was first
crystallized and refined at 1.6-A resolution. The refined structure was
virtually identical to the conformation reported and the electron density at the
active site was interpreted as a pentapeptide Thr-Pro-Gly-Val-Tyr derived from
autolysis of the enzyme (residues 224-228). The chymotrypsin-dipeptide complex
was obtained by soaking the crystals of gamma-chymotrypsin in a solution
saturated with the dipeptide inhibitor. The crystal structure of the complex has
been refined at 1.8-A resolution to a crystallographic R-factor of 18.1%. The
structure of gamma-chymotrypsin in the complex agreed fairly well with that of
gamma-chymotrypsin per se with a rmsd of 0.13 A for all the C alpha carbons. Two
inhibitor molecules were assigned in an asymmetric unit, i.e. one in the active
site and the other at the interface of two symmetry-related enzyme molecules. In
both sites dipeptides adopted very similar folded conformations, in which side
chains of D-Leu-Phe are spatially proximal. In the active site where the binding
of dipeptide was judged to be a direct cause of inhibition, C-terminal
p-fluorobenzylamide group of the dipeptide, NH-BzlF, was found in the S1
hydrophobic pocket. At the bottom of this pocket, the p-fluorine atom hydrogen
bonded with a water molecule, probably to enhance the inhibitory activity. The
stereospecific interaction of R and S isomers of the dipeptide with C-terminal
NH-C*H(CH3)-C6H5 was well explained by the space available for methyl
replacement in the complex. The hydrophobic core constructed by side chains of
D-Leu-Phe was found at the broad S2 site. Interestingly, a novel interaction was
found between the inhibitor Phe residue and chymotrypsin His57, the phenyl of
Phe and the imidazole of His being in a pi-pi stacking interaction at a distance
3.75 A.
|
 |
|
Secondary reference #1
|
 |
|
Title
|
 |
Gamma-Chymotrypsin is a complex of alpha-Chymotrypsin with its own autolysis products.
|
 |
|
Authors
|
 |
M.Harel,
C.T.Su,
F.Frolow,
I.Silman,
J.L.Sussman.
|
 |
|
Ref.
|
 |
Biochemistry, 1991,
30,
5217-5225.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
Secondary reference #2
|
 |
|
Title
|
 |
Structure of gamma-Chymotrypsin in the range ph 2.0 to ph 10.5 suggests that gamma-Chymotrypsin is a covalent acyl-Enzyme adduct at low ph.
|
 |
|
Authors
|
 |
M.M.Dixon,
R.G.Brennan,
B.W.Matthews.
|
 |
|
Ref.
|
 |
Int J Biol Macromol, 1991,
13,
89-96.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
Secondary reference #3
|
 |
|
Title
|
 |
Is gamma-Chymotrypsin a tetrapeptide acyl-Enzyme adduct of alpha-Chymotrypsin?
|
 |
|
Authors
|
 |
M.M.Dixon,
B.W.Matthews.
|
 |
|
Ref.
|
 |
Biochemistry, 1989,
28,
7033-7038.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
|
 |
|
|
|
|
 |